Clinical dosimetry in the treatment of bone tumors: Old and new agents

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 2, 2011, Pages 198-204

  Hindorf, C ^a   Flux, G D ^b   Ibisch, C ^a   Kraeber Bodere F ^c  

^a LUNAM UNIVERSITÉ   (France)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Rene Gauducheau Cancer Center   (France)

Author keywords

Neoplasm metastasis; Radionuclide therapy; Radiotherapy planning, computer assisted

Indexed keywords

ALPHARADIN; LEXIDRONAM SAMARIUM SM 153; MICROSPHERE; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; RADIUM 223 CHLORIDE; RENIUM 186 HEDP; STRONTIUM 89; TIN 117M DTPA; UNCLASSIFIED DRUG;

ANATOMICAL VARIATION; BODY SURFACE; BONE METASTASIS; BONE TUMOR; CANCER RADIOTHERAPY; CLINICAL PRACTICE; DOSIMETRY; HUMAN; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL (TOPIC); RADIATION PROTECTION; RADIOACTIVITY; RADIOISOTOPE THERAPY; REVIEW; SKELETON; TUMOR MODEL; UNSPECIFIED SIDE EFFECT;

BONE NEOPLASMS; HUMANS; PAIN; PALLIATIVE CARE; PHOSPHORUS RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIUM; RHENIUM; SAMARIUM; STRONTIUM RADIOISOTOPES; TIN RADIOISOTOPES;

EID: 79957662849     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005;46(1Suppl.):38S-47S.
2. Kraeber-Bodere F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvment. Eur J Nucl Med 2000;27:1487-93.
3. Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008;35:1934-40.
4. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry - standardization of nomenclature. J Nucl Med 2009;50:477-84.
5. Beddoe AH, Darley PJ, Spiers FW. Measurements of trabecular bone structure in man. PhysMedBiol 1976;21:589-607.
6. Beddoe AH. Measurements of the microscopic structure of cortical bone. Phys Med Biol 1977;22:298-308. (Pubitemid 8060917)
7. ICRP Publication 30, Part 1, Limits for Intakes of Radionuclides by Workers 1980.
8. Snyder WS, Ford MR, Warner GG, Watson SB. "S", absorbed dose per unit cumulated activity for selected radionuclides and organs. New York, NY: The Society of Nuclear Medicine; 1975.
9. Snyder WS, Ford MR, Warner GG. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogenous phantom 1978. MIRD Pamphlet No. 5, Revised.
10. Stabin MG. MIRDOSE: Personal Computer Software for Internal Dose Assessment in Nuclear Medicine. J Nucl Med 1996;37:538-46.
11. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85:294-310. (Pubitemid 36999340)
12. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The Second-Generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine. J Nucl Med 2005;46:1023-7. (Pubitemid 43733519)
13. Eckerman KF, Stabin MG. Electron absorbed fractions and dose conversion factors for red marrow and bone by skeletal regions. Health Phys 2000;78:199-214. (Pubitemid 30061096)
14. Bouchet LG, Bolch WE. A three-dimensional transport model for determining absorbed fractions of energy for electrons within cortical bone. J Nucl Med 1999;40:2115-24. (Pubitemid 30022030)
15. Bouchet LG, Jokisch DW, Bolch WE. A three-dimensional transport model for determining absorberd fractions of energy for electrons within trabecular bone. J Nucl Med 1999;40:1947-66. (Pubitemid 29523592)
16. Bouchet LG, Bolch WE, Howell RW, Rao DV. S Values for radionuclides localized Within the skeleton. J Nucl Med 2000;41:189-212.
17. Watchman CJ, Jokisch DW, Patton PW, Rajon DA, Sgouros G, Bolch WE. Absorbed fractions for alpha-particles in tissues of trabecular bone: considerations of marrow cellularity within the ICRP reference male. J Nucl Med 2005;46:1171-85. (Pubitemid 43741080)
18. Whitwell JR, Spiers FW. Calculated beta-ray dose factors for trabecular bone. PhysMedBiol 1976;21:16-38.
19. Stabin MG, Eckerman KF, Bolch WE, Bouchet LG, Patton PW. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm 2002;17:427-33.
20. Shah AP, Bolch WE, Rajon DA, Patton PW, Jokisch DW A paired-image radiation transport model for skeletal dosimetry. J Nucl Med 2005;46:344-53. (Pubitemid 43073446)
21. Brindle JM, Myers SL, Bolch WE. Correlations of total pelvic spongiosa volume with both anthropometric parameters and computed tomography-based skeletal size measurements. Cancer Biother Radiopharm 2006;21:352-63. (Pubitemid 44696243)
22. Brindle JM, Trindade AA, Shah AP, Jokisch DW, Patton PW, Pichardo JC et al. Linear regression model for predicting patient-specific total skeletal spongiosa volume for use in molecular radiotherapy dosimetry. J Nucl Med 2006;47:1875-83. (Pubitemid 47545011)
23. Pichardo JC, Trindade AA, Brindle JM, Bolch WE. Method for estimating skeletal spongiosa volume and active marrow mass in the adult male and adult female. J Nucl Med. 2007;48:1880-8. (Pubitemid 350099334)
24. Pafundi D, Lee C, Watchman C, Lee C, Bolch W. An image-based skeletal tissue model for the ICRP reference newborn. Phys Med Biol 2009;54:4497-531.
25. Pafundi D, Rajon DA, Jokisch DW, Lee C, Bolch WE. An image-based skeletal dosimetry model for the ICRP reference newborn - internal electron sources. Phys Med Biol 2010;55:1785-814.
26. Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM. Strontium-89 therapy: Measurements of absorbed dose to skeletal metastases. J Nucl Med 1988;29:549-57.
27. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF et al. MIRD Pamphlet No 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37s-61s.
28. International Commission on Radiological P. Basic anatomical and physiological data for use in radiological protection: The skeleton. Oxford, UK: Pergamon Press; 1995.
29. International Commission on Radiological P. Basic anatomical and physiological data for use in radiological protection: Reference values. Oxford, UK: Pergamon; 2002.
30. Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med 1999;40:256-61. (Pubitemid 29077087)
31. International Commission on Radiological P. Radiation dose to patients from radiopharmaceuticals. Oxford, UK: Pergamon Press; 1987.
32. Breen SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med 1992;33:1316-23.
33. Blake GM, Zivanovic MA, McEwan AJ, Ackery D. Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986;12:447-54. (Pubitemid 17037569)
34. Blake GM, Zivanovic MA, McEwan AJ, Batty VB, Ackery D. 89Sr radionuclide therapy: Dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. Eur J Nucl Med 1987;13:41-6. (Pubitemid 17093962)
35. Tennvall J, Darte L, Lundgren R, El Hassan M. Palliation of multiple bone metastases from prostatic carcinoma with strontium-89. Acta Oncologica 1988;27:365-69. (Pubitemid 19007180)
36. Krishnamurthy GT, Swailem F, Srivastava SC, Stabin MG, Hays MT, Koral KF et al. Tin-117m(4+)DTPA: Pharmacokinetics and imaging characteristics in patients with metastatic bone pain. J Nucl Med 1997;38:230-7.
37. Srivastava SC, Atkins HL, Krishnamurthy GT, Zanzi I, Silberstein EB, Meinken G et al. Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: A phase I/ II clinical study. Clin Cancer Res 1998;4:61-8. (Pubitemid 28062878)
38. Singh A, Holmes RA, Farhangi M. Pharmacokinetics of 153Sm-EDTMP in metastatic cancer J Nucl Med 1989;30:1814-8.
39. Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993;34:1031-6.
40. Farhangi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992;33:1451-8.
41. Brenner W, Kampen W, Kampen A, Henze E. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med 2001;42:230-6.
42. Kvinnsland Y, Bruland OS, Moe L, Skretting A. A method for measurements of the uptake patterns of two beta-emitting radionuclides in the same tissu section with a digital silicon detector: application to a study of 89Sr-C12 and 153Sm-EDTMP in a dog with spontaneous osteosarcoma. Eur J Nucl Med 2002;29:191-7.
43. Graham MC, Scher HI, Liu GB, Yeh SD, Curley T, Daghighian F et al. Rhenium-186-labeledhydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clin Cancer Res 1999;5:1307-18. (Pubitemid 29282933)
44. Buffa FM, Flux GD, Guy MJ, O'Sullivan JM, McCready VR, Chittenden SJ et al. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer. Eur J Nucl Med Mol Imaging 2003;30:1114-24. (Pubitemid 36988223)
45. Syed R, Bomanji J, Nagabhushan N, Kayani I, Groves A, Waddington W et al. 186Re-HEDP in the treatment of patients with inoperable osteosarcoma. J Nucl Med 2006;47:1927-35. (Pubitemid 47544980)
46. Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451-9.
47. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncology 2007;8:587-94. (Pubitemid 46995621)
48. Hindorf C, Aksnes A-K, Flux GD. Quantitative imaging of 223Ra during radionuclide therapy of bone metastases. J Nucl Med 2008;49(Suppl. 1):326P.
49. Hindorf C, Flux GD, Lewington VJ, Aksnes A-K, Harris P, Parker C. A biodistribution and dosimetry study of therapeutic 223Ra-chloride (Alpharadin) in patients with osteoblastic skeletal metastases secondary to hormone refractory prostate cancer. J Nucl Med 2008;49(Suppl. 1):145P.